Creating new ways to trigger immune responses in melanoma and kidney cancer.
Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
This study is looking at new ways to help people with melanoma and kidney cancer by using special treatments that boost the immune system, which might lead to better and longer-lasting results from their current therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10911896 on NIH RePORTER |
What this research studies
This research focuses on developing innovative immunotherapy strategies to improve treatment responses in patients with melanoma and renal cell carcinoma. The approach involves inducing a specific type of cell death that activates the immune system, potentially leading to better long-term outcomes. By exploring mechanisms like necroptosis and pyroptosis, the researchers aim to enhance the effectiveness of existing therapies, particularly immune checkpoint inhibitors. Patients may benefit from new treatment options that could lead to more durable responses to cancer therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with melanoma or renal cell carcinoma who have not responded adequately to current treatments.
Not a fit: Patients with cancers other than melanoma or renal cell carcinoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective immunotherapy options that lead to longer-lasting cancer control.
How similar studies have performed: Other research has shown promising results using similar immunotherapy approaches, indicating potential for success in this area.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Cheng, Emily H — Sloan-Kettering Inst Can Research
- Study coordinator: Cheng, Emily H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.